MedTrace Logo

Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

NCT05633420 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-12-02

No results posted yet for this study

Summary

This study is a multi-center, single-arm, open-label, pilot clinical trial to explore efficacy and safety of Pyramax in mild to moderate COVID-19 patients

Conditions

Interventions

DRUG

Pyramax

Participant body weight * ≥65 kg (Pyramax 4 tablets) * ≥45 kg and \<65 kg (Pyramax 3 tablets)

Sponsors & Collaborators

  • Shin Poong Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Yee Gyung Kwak, MD, Phd · Inje University Ilsan Paik Hospital

  • Jin Soo Lee, MD, Phd · Inha University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-24
Primary Completion
2022-09-06
Completion
2022-11-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633420 on ClinicalTrials.gov